Invion Ltd (ASX: IVX) Share Price and News
About Invion
Invion's product pipeline consists of PhotoSoft, a PDT (Photodynamic Therapy platform) involving a light-sensitive drug to selectively target and kill tumour cells. Preliminary clinical data and case reports are promising, and the company is on its way to larger studies in Australia and New Zealand, with possible registration of this technology. IVX-P02 might offer a new targeted approach to the treatment of cancer via PDT.
Invion Company History
Invion is an Australian biotech company established in 2012 with the purpose of developing new approaches in oncology. First, it focused on respiratory diseases but then moved its focus to the treatment of cancer, transferring its experience to PDT product development. The lead candidate, IVX-P02, is a new approach to cancer treatment by using drugs activated with light that precisely target and kill cancer cells.
The strategic deal that Invion signed with the Hudson Institute of Medical Research in 2017 significantly developed its R&D capabilities. It has been a slow and steady journey but the company has been undertaking Phase I/II studies including in non-melanoma skin cancer and anogenital cancer. Late 2025 saw FDA Orphan Drug Designation for anal cancer, which provides major development incentives if the therapy progresses.
Future Outlook of Invion (ASX: IVX)
The outlook for Invion is cautiously optimistic. Though the development of the PDT drug, IVX-P02, may create potential in treating a variety of cancers, this path to regulatory approval is ongoing, and clinical trials have yet to mature. On the other hand, its partnerships with institutions such as Hudson Institute of Medical Research could hasten such a process.
Not to mention the additional fund-raising that will need to be done and sorting out such a complex regulatory environment. Nevertheless, this program is aimed at working toward some successful advancement of Invion's pipeline and technologies portfolio.
With successful preclinical data and early-stage trials underway in Australia and New Zealand, Invion is poised to play a key role in the future landscape of cancer treatment. The timeline for commercialisation, though, cannot be estimated with clarity until further advanced trial results come through, although this is realistically 4-5 years away.
Is Invion (ASX: IVX) a Good Stock to Buy?
Analysts generally remain cautious on Invion at such an early stage of its clinical trials and with no near-term profitability in sight. While focused on PDT, which does hold potential in the treatment of cancer, this remains a speculative stock as outcomes are dependent on clinical success and, ultimately, regulatory approval. Some would point out promising partnerships, such as that with the Hudson Institute, but in general, they emphasize the extremely high risk of investing in small biotech companies that have not yet attained any revenue or regulatory milestones.
Our Stock Analysis
Invion (ASX:IVX) Surges 20% on Non-Dilutive Funding for Cancer Program
Invion Secures Non-Dilutive Backing to Advance Cancer Therapy Invion (ASX:IVX) saw a sharp rerating today, with the share price rising…
Invion (ASX: IVX) Lights Up as Shares Surge 37% on Global Photosoft Deal
Invion’s Global Photosoft Play Positions It as a Leader in PDT Invion (ASX: IVX) surged 37% today after announcing it…
The 2024 Pitt Street Research Life Sciences Conference is coming up! And you’re invited!
The Pitt Street Research Life Sciences Conference is happening on September 19, 2024! The Life Sciences sector in Australia and…
Invion (ASX:IVX): Using Photodynamic Therapy to fight cancer
Unless you’re a professional dermatologist, you may not have ever heard of Photodynamic Therapy, let alone thought of it as…
Frequently Asked Questions
Invion is at the forefront with a method called PhotoDynamic Therapy (PDT) for cancer treatment. They use a special agent, IVX-PDT, drawn from their Photosoft™ Technology, aiming to treat cancer more effectively with fewer side effects.